Bayer AG announced plans for its pharmaceutical division to achieve growth starting in 2027, with an aim for a 30% operating margin by 2030. Key therapeutic areas of focus will include cardiology, oncology, chronic kidney disease, and women’s health. The company is leveraging advancements in artificial intelligence and innovative partnerships to enhance its drug development capabilities. Bayer’s commitment to using cutting-edge research strategies, along with recent drug approvals and a strong drug portfolio, positions it for stable growth despite challenging conditions, including setbacks in Ukraine.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://en.interfax.com.ua/news/economic/1156163.html
